Phase 1b/2a Trial of CNP-103 for Stage 3 Type 1 Diabetes Initiated
COUR Pharmaceutical has initiated Phase 1b/2a clinical trial for CNP-103 in adolescents and adults with recently diagnosed Stage 3 Type 1 Diabetes.
Company
Pharmaceutical intelligence for COUR Pharmaceutical with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.